Ertapenem
- Atc Codes:J01DH03
- CAS Codes:153832-38-3#153832-46-3
- PHARMGKB ID:153832-38-3#153832-46-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Invanz; Cyprus: Invanz; Czech Republic: Invanz; Denmark: Invanz; Estonia: Invanz; Finland: Invanz; France: Invanz; Germany: Invanz; Greece: Invanz; Hungary: Invanz; Ireland: Invanz; Italy: Invanz; Latvia: Invanz; Lithuania: Invanz; Netherlands: Invanz; Poland: Invanz; Portugal: Invanz; Romania: Invanz; Slovakia: Invanz; Spain: Invanz; Sweden: Invanz; UK: Invanz.
North America
Canada: Invanz; USA: Invanz.
Latin America
Argentina: Invanz; Brazil: Invanz.
Drug combinations
Chemistry
Ertapenem Sodium: C~22~H~24~N~3~NaO~7~S. Mw: 497.50. (1) [1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, [4R-[3(3S*,5S*), 4α,5β,6 β(R*)]]-; (2)(4R,5S,6S)-3-[[(3S,5S)-5-[(m-Carboxyphenyl)carbamoyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, monosodium salt. CAS-153832-38-3; CAS-153832-46-3 (ertapenem)(2000).
Pharmacologic Category
Antibacterials; Miscellaneous β-Lactams; Carbapenems. (ATC-Code: J01DH03).
Mechanism of action
A synthetic carbapenem β-lactam antibiotic. Usually bactericidal in action. Antibacterial activity results from inhibition of bacterial cell wall synthesis. Spectrum of activity includes many Gram-positive and -negative aerobic bacteria and some Gram-positive and -negative anaerobic bacteria.
Therapeutic use
Treatment of moderate to severe acute pelvic infections (including postpartum endomyometritis, septic abortion, postsurgical infections), of complicated intra-abdominal infections, of moderate to severe community-acquired pneumonia, of complicated skin and skin structure infections, of complicated urinary tract infections (including pyelonephritis). Prophylaxis of surgical site infection following elective colorectal surgery.
Pregnancy and lactiation implications
Teratogenic effects and fetal harm not shown in animal studies. Adequate, well-controlled studies not conducted in pregnant women and it is unknown whether ertapenem can cause fetal harm. Caution if administered to nursing women.
Unlabeled use
Contraindications
Hypersensitivity to ertapenem, other carbapenems, or any component of the formulation. Anaphylactic reactions to β-lactam antibiotics. If using intramuscularly, known hypersensitivity to local anesthetics of the amide type (the diluent is lidocaine).
Warnings and precautions
Serious hypersensitivity reactions, including anaphylaxis, reported (some without history of previous allergic reactions to β-lactams). Associated with CNS adverse effects, including confusional states and seizures (use caution with CNS disorders). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in renal impairment (increased seizure risk reported in renal dysfunction). Serum concentrations may be reduced to subtherapeutic levels with concomitant use of valproic acid. Lower doses (based upon renal function) often required in the elderly. Doses for I.M. administration are mixed with lidocaine.